Josephine Reyes
Overview
Explore the profile of Josephine Reyes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ye Y, Gaudy A, Thomas M, Reyes J, Burkhardt B, Horan G, et al.
Clin Pharmacol Drug Dev
. 2022 Oct;
11(12):1394-1404.
PMID: 36256505
CC-90001 selectively inhibits c-Jun N-terminal kinase (JNK), a stress-activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC-90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received...
2.
Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, et al.
J Clin Pharmacol
. 2021 Oct;
62(4):494-504.
PMID: 34617279
As a first-in-class, selective, potent inhibitor of the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib was approved by the US Food and Drug Administration in 2017 for the treatment of adult...
3.
Wang X, Chen J, Reyes J, Zhou S, Palmisano M, Li Y
Oncol Ther
. 2020 Jul;
8(1):91-102.
PMID: 32700065
Introduction: The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ...
4.
Li Y, Liu L, Huang L, Wang X, Hoffmann M, Reyes J, et al.
Clin Pharmacol
. 2018 Jul;
10:89-99.
PMID: 30050331
Objective: The aim of this study was to evaluate the bioavailability of a pomalidomide oral liquid suspension relative to the commercial capsule formulation and to assess the food effect on...
5.
Li Y, Wang X, Liu L, Reyes J, Palmisano M, Zhou S
Clin Pharmacol
. 2018 May;
10:53-62.
PMID: 29765255
Objective: To assess whether pomalidomide can distribute into human semen and its duration in human semen. Method: A phase 1, randomized, double-blind, placebo-controlled study (CC-4047-CP-006) was conducted to evaluate the...
6.
Li Y, Liu L, Wang X, Zhang C, Reyes J, Hoffmann M, et al.
J Clin Pharmacol
. 2018 May;
58(10):1295-1304.
PMID: 29762875
Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and...
7.
Li Y, Wang X, Liu L, Zhang C, Gomez D, Reyes J, et al.
Clin Pharmacol Drug Dev
. 2018 May;
8(3):346-354.
PMID: 29746728
Pomalidomide is an immunomodulatory drug and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and...
8.
Tong Z, Atsriku C, Yerramilli U, Wang X, Li Y, Reyes J, et al.
Xenobiotica
. 2018 Jan;
49(2):200-210.
PMID: 29320949
1. The absorption, distribution, metabolism and excretion of enasidenib were studied following a single oral dose of [C]enasidenib to rats (10 mg/kg; 100 μCi/kg) and healthy volunteers (100 mg; 318...
9.
Tran D, Wilson D, Shakeshaft A, Ngo A, Reyes J, Doran C, et al.
AIDS Patient Care STDS
. 2014 Jul;
28(7):365-71.
PMID: 24983389
This study determines an optimal strategy for scaling up ART in Vietnam by examining three initiation thresholds [350 cells/mm(3), 500 cells/mm(3), and treat all people living with HIV (PLHIV) regardless...
10.
Chen N, Weiss D, Reyes J, Liu L, Kasserra C, Wang X, et al.
Cancer Chemother Pharmacol
. 2014 Mar;
73(5):1031-9.
PMID: 24659021
Purpose: Lenalidomide, a weak substrate of P-glycoprotein (P-gp) in vitro, is an oral anticancer drug eliminated predominantly via renal excretion as unchanged compound. The role of P-gp in lenalidomide disposition...